125 studies found for:    primary-progressive multiple sclerosis
Show Display Options
Rank Status Study
21 Active, not recruiting Wahls Paleo Diet and Progressive Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Other: Wahls Paleo Plus;   Other: Wahls Diet
22 Recruiting Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
Conditions: Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Secondary Progressive
Interventions: Drug: ibudilast;   Drug: Placebo
23 Recruiting Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Prednisone;   Drug: Placebo
24 Recruiting Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: MD1003 100mg capsule
25 Completed Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina
Condition: Multiple Sclerosis
Intervention:
26 Completed Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity
Condition: Multiple Sclerosis
Interventions: Drug: Sativex®;   Drug: Placebo
27 Unknown  Cannabis for Spasticity in Multiple Sclerosis
Condition: Multiple Sclerosis
Interventions: Drug: Smoked Cannabis;   Drug: Smoked Cannabis and oral marinol;   Drug: Placebo
28 Terminated Cannabis for Spasticity in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Smoked Cannabis
29 Active, not recruiting Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease
Conditions: Multiple Sclerosis (MS);   Relapsing-Remitting MS;   Primary Progressive MS;   Secondary Progressive MS;   Clinically Isolated Syndrome (CIS)
Intervention: Other: No study treatments administered - blood draws only
30 Recruiting A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
Conditions: Multiple Sclerosis, Remittent Progressive;   Multiple Sclerosis, Primary Progressive;   Relapsing-Remitting Multiple Sclerosis;   Secondary Progressive Multiple Sclerosis;   Multiple Sclerosis
Interventions: Drug: Placebo;   Drug: fampridine (BIIB041)
31 Active, not recruiting Sunphenon in Progressive Forms of Multiple Sclerosis
Condition: Primary or Secondary Chronic-progressive Multiple Sclerosis
Interventions: Drug: Sunphenon EGCG;   Drug: Placebo
32 Recruiting Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis
Conditions: Relapsing Remitting MS;   Secondary Progressive MS;   Primary Progressive MS
Interventions: Dietary Supplement: Caprylic Triglyceride;   Dietary Supplement: Placebo
33 Unknown  The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis
Condition: Multiple Sclerosis (Primary or Secondary Progressive Phase).
Intervention: Drug: Erythropoietin
34 Recruiting Prognosis Value of the Neuronal Damage in Early Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: PET with 11C-Flumazenil
35 Unknown  Evaluation of Efficiency of Ritalin in Multiple Sclerosis (MS) Patients
Conditions: Relapsing Remitting Multiple Sclerosis;   Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Ritalin
36 Completed Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Daclizumab
37 Recruiting Quantified Balance Measures During Stance and Gait: Multiple Sclerosis Patients. A Longitudinal Clinical Study
Condition: Balance Control
Intervention:
38 Active, not recruiting Using Optical Coherence Tomography to Capture Retinal Microvascular Changes Associated With Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention:
39 Unknown  Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis
Conditions: Autoimmune Diseases;   Immune System Diseases;   Demyelinating Diseases;   Nervous System Diseases;   Demyelinating Autoimmune Diseases, CNS;   Autoimmune Diseases of the Nervous System
Intervention: Other: Autologous mesenchymal stem cells from adipose tissue.
40 Active, not recruiting A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis
Condition: Secondary Progressive Multiple Sclerosis
Interventions: Drug: BG00002 (Natalizumab);   Drug: Placebo

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years